Incyte latarcibart Phase 1/2 data

Incyte announced complete safety and efficacy data from the Phase 1/2 multidose study of VGA039 (latarcibart), a novel monoclonal antibody targeting Protein S for von Willebrand disease (VWD). The data, presented at the ISTH 2026 Congress in Paris, showed an 81% median reduction in annualized bleeding rate across all VWD types and bleed categories. Latarcibart was administered once monthly subcutaneously and was safe and well tolerated. The pivotal Phase 3 VIVID-6 trial is currently enrolling. Incyte acquired latarcibart in July 2026 through its acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics. The FDA has granted latarcibart Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations.